Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.

Kiniksa Pharmaceuticals, Ltd.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kiniksa Pharmaceuticals (KNSA), REPRO-MED Systems (K...

Analysts Are Bullish on Top Healthcare Stocks: Kiniksa Pharmaceuticals (KNSA), REPRO-MED Systems (KRMD)

Teknosa Ic ve Dis Ticaret AS ( ($TR:TKNSA) ) just unveiled an announcement. Teknosa İç ve Dış Ticaret A.Ş. has released its interim summary financi...

Teknosa’s H1 2026 Interim Financials Receive Clean Limited Review

The latest update is out from Teknosa Ic ve Dis Ticaret AS ( ($TR:TKNSA) ). Teknosa İç ve Dış Ticaret A.Ş. has released its unconsolidated operatin...

Teknosa’s Mid‑Year Operating Review Clears Limited Assurance Check

Teknosa Ic ve Dis Ticaret AS ( ($TR:TKNSA) ) has issued an update. Teknosa İç ve Dış Ticaret AŞ announced that its non-consolidated financial state...

Teknosa Management Confirms Fair Presentation of H1 2026 Unconsolidated Results

Teknosa Ic ve Dis Ticaret AS ( ($TR:TKNSA) ) has shared an update. Teknosa reported flat first-half 2026 revenue of TL 46.4 billion amid a challeng...

Teknosa holds 1H 2026 sales flat as margins compress and strategic transformation accelerates

Teknosa Ic ve Dis Ticaret AS ( ($TR:TKNSA) ) has provided an update. Teknosa İç ve Dış Ticaret AŞ has resolved to appoint Murat Pınar to a vacant s...

Teknosa Names New Board Member After Resignation

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kiniksa Pharmaceuticals (KNSA) and Cullinan Manageme...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KNSA	$76.75	0.00%	451.33K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KNSA	$76.75	0%	451.33K
3
4
5
6

KNSA

Get Kiniksa Pharmaceuticals, Ltd. Data in Excel

Get Kiniksa Pharmaceuticals, Ltd. Data in Excel